Cohort B of the Pivotal Study to Evaluate the Safety and Effectiveness of the NovaCross™ Micro-catheter

Inclusion Criteria:

- Adult aged 25-80

- Patient understands and has signed the study informed consent form

- Patient has an angiographic documented Chronic Total Occlusion (i.e. >3 months
occlusion duration) showing distal TIMI flow 0, with a reference diameter of at least
2 millimeters.

- Left ventricle ejection fraction > 25%

Exclusion Criteria:

- Patient unable to give informed consent.

- Elevated CK-MB or troponin at baseline

- Patient is known or suspected not to tolerate the contrast agent

- Chronic Total Occlusion is located in aorto-ostial location, SVG CTO, in-stent
occlusion

- Appearance of a fresh thrombus or intraluminal filling defects

- Intolerance to Aspirin and/or inability to tolerate a second antiplatelet agent
(Clopidogrel and Prasugrel and Ticagrelor)

- Cardiac intervention within 4 weeks of the procedure

- Severe renal insufficiency with eGFR<30 ml/min/1.72 m2

- Congestive heart failure [New York Heart Association (NYHA) Class III\IV] CSA Class IV

- Life expectancy < 2 years due to other illnesses

- Acute or unstable medical disorder/disease that may cause a risk to patient,
including:

i. Recent myocardial infarction (MI) (within the past two weeks) ii. Significant
anemia (e.g. hemoglobin < 8.0 mg / dl) iii. Recent major cerebrovascular event
(history of stroke or TIA within 1 month) iv. Severe uncontrolled systemic
hypertension (e.g., >180/100 mmHg) v. Unstable angina requiring emergent percutaneous
trans-luminal coronary angioplasty (PTCA) or coronary artery bypass graft (CABG)